Clarkston Capital Partners LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 2.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 288,380 shares of the biopharmaceutical company’s stock after buying an additional 5,555 shares during the period. Clarkston Capital Partners LLC’s holdings in Pfizer were worth $10,295,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Day & Ennis LLC grew its holdings in shares of Pfizer by 1.9% during the first quarter. Day & Ennis LLC now owns 28,986 shares of the biopharmaceutical company’s stock worth $992,000 after purchasing an additional 531 shares during the last quarter. New England Asset Management Inc. grew its holdings in shares of Pfizer by 27.9% during the first quarter. New England Asset Management Inc. now owns 150,483 shares of the biopharmaceutical company’s stock worth $5,149,000 after purchasing an additional 32,867 shares during the last quarter. Soros Fund Management LLC purchased a new position in shares of Pfizer during the first quarter worth about $1,067,000. Gotham Asset Management LLC grew its holdings in shares of Pfizer by 24.4% during the first quarter. Gotham Asset Management LLC now owns 944,660 shares of the biopharmaceutical company’s stock worth $32,317,000 after purchasing an additional 185,286 shares during the last quarter. Finally, BlueCrest Capital Management Ltd grew its holdings in shares of Pfizer by 105.2% during the first quarter. BlueCrest Capital Management Ltd now owns 164,203 shares of the biopharmaceutical company’s stock worth $5,617,000 after purchasing an additional 84,191 shares during the last quarter. Institutional investors own 69.75% of the company’s stock.

In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Insiders sold a total of 29,450 shares of company stock worth $1,065,220 in the last ninety days. 0.06% of the stock is owned by corporate insiders.

Several brokerages have issued reports on PFE. Morgan Stanley set a $41.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Friday. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, January 2nd. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Friday, December 15th. UBS Group set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Finally, Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $38.88.

Pfizer Inc. (PFE) opened at $36.86 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a twelve month low of $30.90 and a twelve month high of $37.35. The stock has a market capitalization of $219,710.00, a PE ratio of 22.61, a P/E/G ratio of 2.46 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the company posted $0.61 earnings per share. The business’s revenue was up .9% on a year-over-year basis. analysts expect that Pfizer Inc. will post 2.59 EPS for the current year.

Pfizer announced that its Board of Directors has authorized a share buyback plan on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s management believes its shares are undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 3.69%. The ex-dividend date of this dividend is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is currently 78.53%.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/clarkston-capital-partners-llc-has-10-30-million-holdings-in-pfizer-inc-pfe/1798340.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.